- Home
- Platform
- Services
- Protein Engineering Directed Evolution Services
- Protein Engineering Rational Design Services
- Protein Synthesis Services
- Protein Modification Services
- Solutions
- COMPANY
Over the years, the introduction of vaccines for many different diseases has resulted in a significant reduction in the global burden of viral disease. Vaccines that elicit protective broadly neutralizing antibody (bNAb) responses are therefore critical for the treatment and prevention of viral infections. With its advanced protein engineering platform established over the years, Creative BioMart has successfully developed multiple stable viral proteins and produced more effective vaccine candidates against HIV and other viruses. Our scientists are committed to providing fully customized viral vaccine production solutions to customers around the world.
Vaccines refer to whole-cell-based organisms, such as live, attenuated or dead, inactivated bacteria or viruses. Today, the World Health Organization (WHO) considers vaccination to be the most cost-effective strategy for controlling infectious diseases. Pharmaceutical companies have been very successful in producing safe, effective vaccines to prevent seasonal flu epidemics. However, current vaccine production involves many time-consuming steps and extensive quality control testing to ensure vaccine safety and efficacy. The advent of rational, computational and combinatorial approaches holds great promise for applying protein engineering principles to viral vaccine and immunotherapy development. In addition, scientists have made great strides in designing new viral immunogens and antibodies, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), and the malaria parasite.
Fig 1. Computational and Combinatorial Redesign of HIV-1 gp120 Analogs. (Koellhoffer JF, et al., 2014)
Most viral vaccines work by inducing the production of antibodies that block infection or reduce viral load, thereby making cellular immunity effective. Creative BioMart focuses on neutralizing antibodies, which bind viruses as vaccines to prevent infection. We have successfully isolated protective neutralizing antibodies from those viruses that have high antigenic diversity or that do not elicit protective broadly neutralizing antibody (bNAb) responses during natural infection, and employed protein engineering strategies to design eliciting bNAbs or design novel Immunogens for bNAbs. The most common viral vectors we use are:
(1) Retroviruses (for inserting DNA; in vitro or in vivo).
(2) Adenovirus (for transient expression).
(3) Lentivirus (for transient and stable gene expression in vitro).
The unstable nature of viral envelope glycoproteins has been a major obstacle to the development of effective vaccines against HIV and other viruses. We employed a high-throughput protein stabilization strategy to produce stable proteins with eliciting protective immune responses, allowing the identification of viral protein variants with greater stability but retaining their native protein structure. Here we can help you develop a variety of vaccines that elicit neutralizing antibodies against highly diverse viruses, including HIV, HPV, Hepatitis B, Respiratory Syncytial Virus (RSV), Dengue, Zika, Malaria and other diseases.
In order to provide customized high-quality viral vaccine to our global customers, we use advanced protein engineering strategies to design multiple immunogens against rapidly evolving pathogens.
Creative BioMart has in-depth knowledge and experience of the tools and processes involved in vaccines development, and provides professional solutions for viral vaccines production. Whether your vaccines are in the discovery and screening stages, or are planning vaccines production, please contact us to discuss further details to ensure your next success.
References